FAS and lymphoma: Treatment with DzNep or Ibrutinib, which targets BTK, increased FAS ligand-mediated apoptosis in lymphoma cell lines by abolishing the EZH2-mediated repression of FAS-AS1 expression, leading to decreased expression of sFAS.